HC Wainwright Reiterates “Buy” Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $5.00 price target on the stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Invivyd in a report on Thursday.

Invivyd Stock Performance

IVVD stock opened at $0.73 on Thursday. Invivyd has a one year low of $0.35 and a one year high of $2.74. The firm’s fifty day moving average is $0.76 and its 200 day moving average is $0.76. The firm has a market cap of $87.15 million, a PE ratio of -0.61 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last posted its earnings results on Thursday, May 15th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). Invivyd had a negative net margin of 389.01% and a negative return on equity of 165.24%. The business had revenue of $11.30 million for the quarter, compared to analyst estimates of $34.45 million. Research analysts predict that Invivyd will post -1.64 earnings per share for the current fiscal year.

Institutional Trading of Invivyd

Several institutional investors have recently modified their holdings of IVVD. AQR Capital Management LLC raised its position in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares during the last quarter. Nuveen LLC purchased a new stake in Invivyd during the 1st quarter worth approximately $65,000. Invesco Ltd. raised its holdings in shares of Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after acquiring an additional 71,485 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Invivyd during the first quarter valued at approximately $66,000. Finally, Two Sigma Investments LP lifted its position in shares of Invivyd by 125.3% in the fourth quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after acquiring an additional 204,188 shares in the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.